Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola Marries Factor Xa Clot Buster Off To Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal is "strikingly similar" to a collaboration forged with Novartis for an anti-thrombotic earlier this year.
Advertisement

Related Content

Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin
Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin
Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
R&D IN BRIEF
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Portola Anticipates “Best In Class” Status For Novel Phase II Anticoagulant

Topics

Advertisement
UsernamePublicRestriction

Register

PS069815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel